Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: buying weakness is still early and speculative yet, timing is everything

August 17, 2021 7:41am

Remember, Friday is an option’s expiration “witching” session

Pre-open indications: SELLs: 2; BUYs: 3; Maintain SELL: 1

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

There is no breadline for fact and numbers-based share pricing intelligence!

Dow futures are DOWN -0.64% (-229 points), S&P futures are DOWN -0.51% (-23 point) and NASDAQ futures are DOWN -0.40% (-601points)

U.S. stock index futures were lower during early morning trading Tuesday,

European markets were also lower,

Asia-Pacific markets were mostly lower setting the pace to the downside,

Data Docket: retail sales – expected to post a small decline

Henry’omics:

Yesterday, Monday the cell and gene therapy sector sought yet another bottom … might be time to sweeten the portfolio.

While the Dow jumped +0.31%, the S&P 500 +0.26% posting their fifth straight positive session on Monday, as the Nasdaq declined -0.2%.

The S&P 500′s move during Monday’s session was especially notable since the benchmark index has now doubled from its pandemic closing low on March 23, 2020. This marks the fastest bull-market doubling since World War II. <CNBC>

Monday’s evening’s recap: “starting the week, the cell and gene therapy sector exhibits an irregular pulse and heartbeat. Everything is tradeable but, what do investors want to own going forward? My concern is wobbling sentiment post earnings” … https://www.regmedinvestors.com/articles/12051

The Nasdaq closed DOWN – 29.14 points (-0.20%);
The IBB closed down -1.10% and XBI closed down -1.62%;
Sector volume was LOW with 3 of the 5-upside having higher than the 3-month average volume with very LOW volume of 2 of 28-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was up +0.86 points or +5.27% at 16.31
Monday’s percentage (%) of the 5-upside were +0.12% (ALNY) to +3.42% (VCEL) while the 28-downside ranges from -0.48% (KDNY) to -13.75% (BSTG);

Q3/21:

August: 5 positive and 6 negative close
July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

June: 15 positive and 8 negative closes
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?

Biostage (BSTG) closed down -$0.22 to $1.38 with 135 share traded following Friday with 10 shares traded after Thursday and Wednesday with 50 shares traded following Tuesday with 4 shares traded and last Monday’s down -$0.05 with 1060 shares traded.

The Bottom-Line Question: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND foe a year and a half with NO clinical trial initiative … so WHAT is the value proposition WHEN they’re BROKE?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

Pre-open Indications:

BUY on Bounce capacity:

Adverum Biotechnologies (ADVM) closed down -$0.12 and has a positive +$0.05 or +2.25% aftermarket indication;

CRISPR Therapeutics (CRSP) closed down -$4.21 with a positive $0.06 or +0.05% aftermarket indication;

uniQure NV (QURE) closed down -$0.61 and has a positive +$1.25 or +4.38% aftermarket indication;

SELL:

bluebird bio (BLUE) closed down -$0.21 and has a negative -$0.09 or -0.49% aftermarket indication;

Editas Medicine (EDIT) closed down -$2.66 and has a negative -$0.49 or -0.82% aftermarket indication;

The BOTTOM LINE: the alternating cycle of being oversold is the ability to be overbought after multiple sessions

Sector Q2 earnings (26) contributed to the declining slope of many equities; so far released have been weak (3 net incomes and 23 net losses) and as usual, investors are worried that the clinical advances are in-short supply although 2024 seems to be the usual runway length and timing.

Some earnings’ Reports Outstanding:

Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)

Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.

Risk is no doubt increasing as we head into the troublesome August and September months

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is all but, over … my advice, take a chance, roll the dice and then be ready to skim any new highs!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.